Ultragenyx Pharmaceutical has made a proposal to acquire all of the outstanding shares of common stock of Dimension Therapeutics for $5.50 per share, or approximately $138m, in cash at close to be effectuated via a tender offer.
Mustang Bio, a Fortress Biotech company, has announced the expansion of its pipeline of CAR T therapies into CD20-directed immunotherapies.
Inotek Pharmaceuticals announced that it has entered into a definitive merger agreement with US-based gene therapy company Rocket Pharmaceuticals.
Summit Therapeutics announces that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government's Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, has awarded Summit a contract worth up to $62m.
Janssen Sciences Ireland UC has scrapped its ongoing hepatitis C development program citing the growing number of therapies available for treating the disease effectively.
Boehringer Ingelheim and Gubra announce a collaboration and license agreement for the development of novel peptide compounds to treat obesity.
Evotec and the European Investment Bank (EIB) announced that the EIB has granted Evotec an unsecured loan facility of up to €75m to support Evotec's Innovate strategy.
GSK announced that it has exercised the option to obtain an exclusive global license from Adaptimmune for an investigational SPEAR T-cell receptor therapy targeting NY-ESO-1 (GSK3377794).
PATH has received a $120m grant from the Bill & Melinda Gates Foundation to further strengthen its PATH Center for Vaccine Innovation and Access (CVIA), which works across every stage of vaccine research, development, and introduction for diseases in low-resource settings.
Avadel Pharmaceuticals has entered into a license agreement with Serenity Pharmaceuticals, which grants Avadel the sole right to commercialize and further develop Noctiva in the US and Canada.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.